Diagnosis of Zollinger-Ellison syndrome:Increasingly difficult

被引：5

作者：

Tetsuhide Ito ^{[1
]}

Guillaume Cadiot ^{[2
]}

Robert T Jensen ^{[3
]}

机构：

[1] Department of Medicine and Bioregulatory Science,Graduate School of Medical Sciences,Kyushu University,Fukuoka 812-8582,Japan

[2] Hepato-Gastroenterology Service,Centre hospitalier universitaire de Reims,Hospital Robert Debre,F-51092 Reims,France

[3] Digestive Diseases Branch,National Insitutes of Diabetes,Digestive and Kidney Diseases,National Institutes of Health,Bethesda,MD 20892,United States

来源：

World Journal of Gastroenterology | 2012年 / 18卷 / 39期

关键词：

Zollinger-Ellison syndrome; Gastrinoma; Hypergastrinemia; Secretin test; Serum gastrin; Gas-trin; Neuroendocrine tumor;

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

1002 ; 100201 ;

摘要：

In the present paper the increasing difficulty of diag-nosis of Zollinger-Ellison syndrome (ZES) due to issues raised in two recent papers is discussed. These issues involve the difficulty and need to withdraw patients suspected of ZES from treatment with Proton Pump Inhibitors (omeprazole, esomeprazole, lansoprazole, rabeprazole, pantoprazole) and the unreliability of many gastrin radioimmunoassays. The clinical context of each of these important issues is reviewed and the conclusions in these articles commented from the per-spective of clinical management.

引用

页码：5495 / 5503

页数：9

共 47 条

[1] The Zollinger–Ellison Syndrome: Dangers and Consequences of Interrupting Antisecretory Treatment[J] . Pierre Poitras,Marie–Hélène Gingras,Jens F. Rehfeld.Clinical Gastroenterology and Hepatology . 2012 (2)
[2] Diagnosis of the Zollinger–Ellison Syndrome[J] . David C. Metz.Clinical Gastroenterology and Hepatology . 2012 (2)
[3] ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes[J] . Jensen, Robert T,Cadiot, Guillaume,Brandi, Maria L,De Herder, Wouter W,Kaltsas, Gregory,Komminoth, Paul,Scoazec, Jean-yves,Salazar, Ramon,Sauvanet, Alain,Kianmanesh, Reza.Neuroendocrinology . 2012 (2)
[4] Immunocytochemical staining for islet amyloid polypeptide in pancreatic endocrine tumors
Tomita, Tatsuo
[J]. ISLETS, 2011, 3 (06) : 344 - 351
[5] The Zollinger–Ellison Syndrome and Mismeasurement of Gastrin[J] . Jens F. Rehfeld,Marie–Hélène Gingras,Linda Bardram,Linda Hilsted,Jens P. Goetze,Pierre Poitras.Gastroenterology . 2011 (5)
[6] Chromogranin A-Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Modlin, Irvin M.
Gustafsson, Bjorn I.
Moss, Steven F.
Pavel, Marianne
Tsolakis, Apostolos V.
Kidd, Mark
[J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (09) : 2427 - 2443
[7] Gastric acid hypersecretory states: Recent insights and advances[J] . Nauramy Osefo,Tetsuhide Ito,Robert T. Jensen.Current Gastroenterology Reports . 2009 (6)
[8] PPI-Delayed Diagnosis of Gastrinoma: Oncologic Victim of Pharmacologic Success[J] . Hilda Wong,Thomas Yau,Pierre Chan,Irene O. L. Ng,Gavin Chan,Peter Hui,W. L. Law,C. M. Lo,Antony J. Hedley,Richard J. Epstein.Pathology ＆ Oncology Research . 2010 (1)
[9] Clinical use of proton-pump inhibitors but not H＜sub＞2＜/sub＞-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population[J] . Lars Agr＆eacute,us,Tom Storskrubb,Pertti Aro,Jukka Ronkainen,Nicholas J. Talley,Pentti Sipponen.Scandinavian Journal of Gastroenterology . 2009 (5)
[10] Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors[J] . David C. Metz,Robert T. Jensen.Gastroenterology . 2008 (5)

← 1 2 3 4 5 →